Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.jmedchem.0c01467 http://scihub22266oqcxt.onion/10.1021/acs.jmedchem.0c01467 33539089!ä!33539089 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Chem 2022 ; 65 (2): 893-921 Nephropedia Template TP {{tp|p=33539089|t=2022. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections |pdf=|usr=}}{{33539089}} gab.com Text Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections JO: J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=33539089 #FOAvip Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer's disease, and viral infections. The majority of approved antiviral agents are inhibitors of virus-specific targets that are encoded by individual viruses. These inhibitors are narrow-spectrum agents that can cause resistance development. Viruses are dependent on host cellular proteins, including kinases, for progression of their life-cycle. Thus, targeting kinases is an important therapeutic approach to discovering broad-spectrum antiviral agents. As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antiviral activity or are useful in the management of viral infections. Twit Text FOAVip Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections ????J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=33539089 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33539089 #FOAvip English Wikipedia <ref>{{Cite pmid|33539089}}</ref> Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections #MMPMID33539089 Raghuvanshi R; Bharate SB J Med Chem 2022[Jan]; 65 (2): 893-921 PMID33539089show ga Kinases are a group of therapeutic targets involved in the progression of numerous diseases, including cancer, rheumatoid arthritis, Alzheimer's disease, and viral infections. The majority of approved antiviral agents are inhibitors of virus-specific targets that are encoded by individual viruses. These inhibitors are narrow-spectrum agents that can cause resistance development. Viruses are dependent on host cellular proteins, including kinases, for progression of their life-cycle. Thus, targeting kinases is an important therapeutic approach to discovering broad-spectrum antiviral agents. As there are a large number of FDA approved kinase inhibitors for various indications, their repurposing for viral infections is an attractive and time-sparing strategy. Many kinase inhibitors, including baricitinib, ruxolitinib, imatinib, tofacitinib, pacritinib, zanubrutinib, and ibrutinib, are under clinical investigation for COVID-19. Herein, we discuss FDA approved kinase inhibitors, along with a repertoire of clinical/preclinical stage kinase inhibitors that possess antiviral activity or are useful in the management of viral infections. |Antiviral Agents/*therapeutic use[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/virology[MESH] |Drug Approval/legislation & jurisprudence[MESH] |Drug Repositioning[MESH] |High-Throughput Screening Assays[MESH] |Humans[MESH] |Protein Kinase Inhibitors/*therapeutic use[MESH] |SARS-CoV-2/isolation & purification[MESH] |United States[MESH] |United States Food and Drug Administration[MESH]Recent Developments in the Use of Kinase Inhibitors for Management of (epmc).pdf DeepDyve Pubget Overpricing